Pfizer Inc PFE

$29.44 -0.14 (-0.47%)

Valuation

Market cap
168,596,352,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.65
Forward PE
9.99
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
20,816,618
Avg volume
33,309,836
Day's range
$29.25 – $29.69
Shares out
5,699,674,000
Stochastic %K
89%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

TopOptionAlert Oct 19, 10:31 PM
$PFE NOV06 30C · still actionable Zone: $29.23 to $29.65 Invalidation: close under $28.55 Objectives: $31.25, then $33 The math: up 6.1% to the first objective and 12.1% to the second, against 3.0% risk on the invalidation, about 4 to 1 to the second Dear friend, picture a big old ship that spent a long time turning and is finally pointing the way it wants to go. Pfizer eased to $29.44 today after touching $29.88 last week, its highest price in a year, and buyers held the low at $29.25, which tells you the recent strength is still being defended. What that means is simple: this is a swing setup into earnings on November 3, and a push back over that yearly high opens room toward the objectives above, while a close under $28.55 would say the breakout day floor failed and you step aside. P.S. Watch $29.88 first. It is the yearly high from last week, and a close over it would show buyers pushing again, not just defending.
0 replies
taxplanr Oct 19, 7:53 PM
I can't put a number on the blood clots that took out NFL players before the bioweapons from $MRNA $BNTX $PFE can you? https://nypost.com/2026/10/19/sports/jalen-hurts-lost-for-the-season-as-blood-clots-worse-than-eagles-feared/
0 replies
SellasgpsCurativeBAT11 Oct 19, 5:08 PM
$ABBV $AZN $JNJ $PFE $SLS Dr. Stergiou At the May 19 Stifel presentation, CEO Angelos Stergiou said GPS was being administered to patients "even three years out at this point." At the May 27 Cowen oncology summit, he explained that treatment had been extended beyond the original one-year schedule, eventually beyond three years, at the request of physicians who assessed that their patients were benefiting. As a Biostatistician compelling reason to pay attention. Continued treatment years later, with physicians requesting the option to keep dosing, fits the possibility of durable benefit. ✌️🙏❤️‍🩹
1 replies
SellasgpsCurativeBAT11 Oct 19, 3:37 PM
$ABBV $AZN $JNJ $PFE $SLS $380 Billion in patent Expirations Big pharmaceuticals are very aggressive right now. Biotechnology sector is averaging 2 deals every week in 2026. 👇 ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 19, 3:27 PM
$ABBV $AZN $JNJ $PFE $SLS 9 trading days left in October 2026. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 19, 3:25 PM
$SLS $JNJ $PFE $ABBV $AZN Part 2. Timeline of events is condensed in a very short time frame now. Warrants extinguished the uptick will be very violent. $SLS Will trade over 100 million shares on the day GPS Regal Phase 3 Top line data is PR’d. $SLS won’t be a stand alone Co. after GPS Regal pivotal Registrational phase 3 data and will be part of a big pharmaceutical suitor. ✌️🙏❤️‍🩹
0 replies
PFElinepfrenzy1990 Oct 19, 12:45 PM
$PFE - Stinky day incoming!
1 replies
INEEDMONEY87 Oct 19, 11:46 AM
$PFE just waiting for satans dildo to come out again…
1 replies